Core Viewpoint - Eli Lilly is expanding the applications of GLP-1 drugs beyond weight loss, with promising results from the TOGETHER-PsA study showing the combination of Taltz and Zepbound significantly improves outcomes in patients with psoriatic arthritis and obesity [4][8]. Group 1: Clinical Data and Efficacy - The TOGETHER-PsA study demonstrated that 31.7% of patients receiving the combination therapy achieved at least a 50% improvement in disease activity (ACR50) and a weight loss of ≥10%, compared to only 0.8% in the Taltz monotherapy group [4]. - In secondary endpoints, 33.5% of patients in the combination group achieved ACR50, representing a 64% relative increase over the Taltz monotherapy group, indicating a synergistic effect of the two mechanisms in treating PsA [6]. Group 2: Safety Profile - The safety profile of the combination therapy was consistent with the known safety profiles of both drugs, with common adverse events including nausea, diarrhea, constipation, and injection site reactions, and no new safety signals were reported [6]. Group 3: Strategic Importance and Market Potential - Taltz, which generated approximately $3.2 billion in revenue for Eli Lilly in 2024, is expected to continue growing, potentially reaching around $4 billion by 2029 [7]. - The upcoming expiration of Taltz's core patent in 2028 highlights the strategic significance of the TOGETHER-PsA study, as it is the first controlled trial to demonstrate the additional benefits of combining GLP-1 drugs with PsA biologics [8]. Group 4: Integrated Treatment Approach - The study supports the potential of an integrated treatment approach targeting both immune inflammation and metabolic abnormalities, which could enhance the standard of care for PsA [9]. - The combination of Taltz and Zepbound not only extends the clinical value and lifecycle of Taltz but also positions Zepbound as a systemic disease management tool, expanding its potential indications [9].